Barclays analyst Gena Wang maintained a Sell rating on Puma Biotechnology (PBYI – Research Report) today and set a price target of $2.00. The company’s shares closed yesterday at $4.96.
Wang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Legend Biotech, and Vertex Pharmaceuticals. According to TipRanks, Wang has an average return of 9.0% and a 45.36% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Puma Biotechnology with a $4.33 average price target.
Based on Puma Biotechnology’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $72.18 million and a net profit of $12.27 million. In comparison, last year the company earned a revenue of $65.68 million and had a GAAP net loss of $5.61 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology (PBYI) Company Description:
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
